Adaptive Pharmacogenomics, LLC

Researchers at the Harvard School of Public Health have found that children and adolescents living in non-smoking homes in counties with laws promoting smoke-free public places have significantly lower levels of a common biomarker of secondhand smoke exposure than those living in counties with no smoke-free laws.

AMG 386 Treatment Response Increased With Dose And Exposure AMG 386 Moving Into Phase 3 For Recurrent Ovarian Cancer Separately, Two Analyses Provide Evidence Of Biomarker As Predictor Of Tumor Response To Motesanib THOUSAND OAKS, Calif. , June 6, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.   The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

Pharmacol Ther. 2010 Apr;126(1):69-81

Authors: Ishikawa T, Sakurai A, Hirano H, Lezhava A, Sakurai M, Hayashizaki Y

Pharmacogenomics, the study of the influence of genetic factors on drug action, is increasingly important for predicting pharmacokinetics profiles and/or adverse reactions to drugs.

Actas Dermosifiliogr.

Transplant Proc. 2010 Jan-Feb;42(1):257-9

Authors: Larriba J, Imperiali N, Groppa R, Giordani C, Algranatti S, Redal MA

The tacrolimus is metabolized primarily by CYP3A5, a member of the single nucleotide polymorphism family. It shows cytochrome P450 (SNP) in intron 3, which consists of a change of base, G for A, producing a stop codon. The result is a nonfunctional protein (allele *3).

Clin Pharmacol Ther. 2010 Jun;87(6):635-8

Authors: Khoury MJ

In this commentary, I discuss how the promise of genomics and personalized medicine (GPM) is currently not matched by the evidence that supports its use in clinical practice.

J Diabetes Sci Technol. 2009;3(4):705-9

Authors: Vella A

There is a relative dearth of studies designed to elucidate genetic variation that can explain differences in the response to diabetes pharmacotherapy. When designing such studies, appropriate consideration of the various nongenetic variables that can affect the treatment response is necessary.

J Diabetes Sci Technol. 2009;3(4):680-4

Authors: Abrahams E, Silver M

Personalized medicine may be considered an extension of traditional approaches to understanding and treating disease, but with greater precision. Physicians may now use a patient's genetic variation or expression profile as well as protein and metabolic markers to guide the selection of certain drugs or treatments.

Drug Metab Pharmacokinet. 2010;25(1):62-71

Authors: Bai JP

The complex transporter-cytochrome P450 (CYP) enzyme interplay in the disposition of drugs makes it very challenging to address the safety of clinical drug interactions. Thus, two major subjects are discussed herein.